Inflammatory markers response to crocin supplementation in patients with type 2 diabetes mellitus: A randomized controlled trial

Inflammation and oxidative stress is a risk factor for the development of long‐term consequences in patients with type 2 diabetes mellitus (T2DM). This study was designed to investigate the effects of crocin consumption on oxidative stress and inflammatory markers in patients with T2DM. In this clinical trial with a parallel‐group design, 50 patients with T2DM were randomly assigned to either the crocin or the placebo group. The crocin group received 15 mg crocin twice daily, whereas the placebo group received corresponding placebos. At baseline and the end of week 12, serum high sensitive C‐reactive protein (hs‐CRP), interleukin‐6 (IL‐6), tumor necrosis factor‐ɑ (TNF‐ɑ), nuclear factor‐κB (NF‐κB), and malondialdehyde (MDA) were measured. Compared with placebo group, crocin reduced hs‐CRP (−1.03 vs. 1.42, p = .007), TNF‐ɑ (−0.8 vs. 0.28, p = .009), and NF‐κB (−0.39 vs. 0.01, p = .047) after 12 weeks intervention; these improvements were also significant in comparison with the baseline values. Plasma IL‐6 decreased significantly in the crocin group at the end of week 12 compared to baseline ( p = .037), whereas no significant change was observed in the placebo group. Plasma concentration of MDA did not change within and between groups after intervention. This study indicates that daily administration of 30 mg crocin supplement to patients with T2DM reduces the concentrations of hs‐CRP, TNF‐ɑ, and NF‐κB which are involved in the pathogenesis of complications of T2DM.